The syntactic rules for ellipses are standardized by the 1983 Polska Norma document PN-83/P-55366, Zasady składania tekstów w języku polskim (Rules for Setting Texts in Polish). In Russian
The combination "ellipsis+period" is replaced by the ellipsis. The combinations "ellipsis+exclamation mark" and "ellipsis+question mark" are written in this way: !.. ?.. In Japanese
The most common character corresponding to an ellipsis is called 3-ten rīdā ("3-dot leaders", …). 2-ten rīdā exists as a character, but it is used less commonly. In writing, the ellipsis consists usually of six dots (two 3-ten rīdā characters, ……). Three dots (one 3-ten rīdā character) may be used where space is limited, such as in a header. However, variations in the number of dots exist. In horizontally written text the dots are commonly vertically centered within the text height (between the baseline and the ascent line), as in the standard Japanese Windows fonts; in vertically written text the dots are always centered horizontally. As the Japanese word for dot is pronounced "ten", the dots are colloquially called "ten-ten-ten" (てんてんてん, akin to the English "dot dot dot").In text in Japanese media, such as in manga or video games, ellipses are much more frequent than in English, and are often changed to another punctuation sign in translation. The ellipsis by itself represents speechlessness, or a "pregnant pause". Depending on the context, this could be anything from an admission of guilt to an expression of being dumbfounded at another persons words or actions.
Based on its mechanism of action, treatment with may pose a risk to reproductive capacity. Pharmacology
Faricimab is a 150kDa-sized bispecific antibody whose molecular structure allows a high affinity bond to both vascular endothelial growth factor A (VEGF-A) and Angiopoietin (Ang-2). By blocking the action of these two growth factors, faricimab decreases migration and replication of endothelial cells allowing for stabilization of vascular structures, thereby decreasing vascular leakage. Faricimab has shown improved and sustained efficacy in comparison to agents that only target the VEGF pathway. History
In 2016, pre-clinical studies looking at the mechanism of action behind faricimab showed that by blocking Ang-2, one of the drugs targets, there was decreased endothelial barrier breakdown in blood vessels. In 2017, phase I studies in neovascular age related macular degeneration (nAMD) showed that the drug was safe to use in people and well tolerated. Society and culture
Legal status
On 21 July 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vabysmo, intended for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME). The applicant for this medicinal product is Roche Registration GmbH. Faricimab was approved for medical use in the European Union in September 2022. Names
Faricimab is the International Nonproprietary Name (INN). Faricimab was formerly named RG7716.